Peer group leading results and the special dividend roadmap with Tekcapital CEO Dr Clifford Gross

The UK Investor Magazine was delighted to welcome Dr Clifford Gross, CEO of Tekcapital, back to the podcast to delve into the technology incubator’s 2024 portfolio results and what could be in store in 2025.

We start by reviewing the portfolio’s performance in 2024, paying particular attention to the impact of MicroSalt and GenIP’s IPOs.

Dr Clifford Gross outlines plans for Guident’s proposed NASDAQ listing and what it means for Tekcapital’s overall strategy.

We finish by exploring the roadmap for Tekcapital to return net asset value growth to shareholders via special dividends.

FTSE 100 ticks higher, BAE Systems soars

The FTSE 100 rallied on Monday amid a broad European rally driven by defence stocks sparked by positioning for greater defence spending.

Donald Trump’s approach to Ukraine peace negotiations has strengthened the argument that Europe must bolster its armed forces with investors quickly buying up defence shares, including London’s BAE Systems and Rolls Royce.

“European markets pushed ahead on Monday amid talk of greater defence spending, M&A activity and a series of important political meetings,” said Russ Mould, investment director at AJ Bell.

“Ukraine peace talks topped the agenda, while Chinese president Xi Jinping undertook a rare meeting with some of China’s biggest tech firms to boost business sentiment.”

BAE Systems was the top FTSE 100 riser as investors tweaked their portfolios to reflect a possible increase in defence spending.

“Comments by secretary general Mark Rutte that NATO members will have to boost their defence spending by ‘considerably more than 3%’ of GDP put a rocket underneath defence stocks. BAE Systems jumped to the top of the FTSE 100 risers list as investors hoped its earnings prospects would be greatly improved. Mid-cap defence player Chemring also enjoyed a boost.

BAE Systems shares surged by 7% while Rolls-Royce gained 3%, reaching an all-time record high.

Away from the defence sector, Barclays and NatWest enjoyed buying pressure following a bout of profit-taking last week. Both banks dipped after releasing their results, but the weakness proved short-lived, with investors piling back in and sending the pair higher by more than 3%.

Barratt Redrow added 1%, and Persimmon was flat after Rightmove said house prices showed signs of slowing, although sales remained robust.

“UK asking prices rose modestly from January to February, slightly below the typical seasonal gain, with the year-on-year increase also slowing according to data from Rightmove,” said Matt Britzman, senior equity analyst, Hargreaves Lansdown.

“Despite this, sales activity remains solid, with strong buyer demand and an uptick in new sellers. After a tough 2024, housebuilders have generally been upbeat about the outlook for 2025, and the steady market activity supports some cautious optimism.”

AIM movers: Springfield Properties land sale and Europa Metals deal terminated

10

Tekcapital (LON: TEK) has published a portfolio update showing the progress made during 2024. This was a period when investee companies MicroSalt (LON: SALT) and GenIP (LON: GNIP) joined AIM. The remaining unquoted investee company Guident is set to join Nasdaq this year. The value of the investment portfolio increased 38% to $64.2m. NAV is 25p/share. The share price improved 9.41% to 10p, which is still a 60% discount to NAV. (see Tekcapital shares gain after releasing portfolio review, reaffirms special dividend strategy – UK Investor Magazine)

Scotland-based housebuilder Springfield Properties (LON: SPR) is selling land holdings in central Scotland to Barratt for £64.2m and could sell further sites. This will contribute a significant profit in the year to May 2025. Springfield Properties will refocus on the north of Scotland. Trading has been weak so far in this financial year. Interim revenues declined 13%, but better margins meant that pre-tax profit recovered from £2m to £3.8m. Singer has downgraded its 2025-26 pre-tax profit forecast by 14% to £14.2m, but the dividend is expected to continue to recover. A net cash position is expected by 2027. The share price rebounded 9.14% to 107.5p.

Thor Energy (LON: THR) has completed the acquisition of 80.2% of Go Exploration and the payment is 466.5 million shares. A further 25 million shares were issued to Orana Corporate for consultancy services. Go Exploration is a hydrogen and helium explorer with a hydrogen and helium exploration licence in South Australia near to the Ramsay-1 and Ramsay-2 discoveries. An independent assessment is due to be published soon. The share price rose 8.33% to 0.65p.

MTI Wireless (MWE) has won a repeat antenna order worth $4m. This will be delivered in the period up to June 2026. The 2024 results will be published on 17 March. The share price increased 3.77% to 55p.

FALLERS

Trading in Europa Metals (LON: EUZ) shares recommenced this morning after the period of exclusivity over the potential purchase of Viridian Metals Ireland, which owns the Tynagh brownfield Pb/Zn/Cu/Ag project in the Republic of Ireland. Europa Metals has been unable to source funding for initial work on the project and is not going ahead with the deal. The share price dipped by one-fifth to 1.6p.

Surgery devices developer Creo Medical (LON: CREO) says core revenues were 74% ahead at £4m in 2024, which is well ahead of the forecast of £3.4m. The distribution operations have been sold leaving the company with net cash. Operating costs were reduced by £5m last year and the full benefit will be in 2025. Creo Medical is expected to remain loss-making, but it will not need to raise additional cash. The share price declined 8.73% to 17.25p.

Orosur Mining (LON: OMI) has completed phase one of its exploration joint venture for the El Pantano gold exploration project in Argentina and has a 51% stake following the $1m investment. Further investment of $2m would mean that Orosur Mining can own 100% of the project. The vendors will retain a 2% net smelter royalty. The plan is to define drill targets. The share price fell 4.05% to 13.625p.

Allergy Therapeutics (LON: AGY) says published data from its phase III G306 study for its grass allergen immunotherapy Grass MATA MPL shows a 20.3% improvement, which is much higher than for trials of other treatments. The treatment requires six injections rather than up to 100 injections and tablets of other treatments. The quality of life improves by 27.7%. A marketing authorisation application has been filed in Germany. The share price slipped 3.85% to 6p, but the share price is still on an upward trend.

Sound Energy (LON: SOU) has appointed Zeus as its nominated adviser and broker. The share price is 3.13% higher at 0.775p.

Tekcapital shares gain after releasing portfolio review, reaffirms special dividend strategy

Tekcapital shares gained on Monday after the UK-based intellectual property investment group issued a year-end portfolio update and affirmed its plans to return capital to shareholders through special dividends.

Tekcapital reported a 38% increase in its investment portfolio value to $64.2 million in 2024, significantly outperforming market benchmarks and peer companies during the year.

The company’s strong performance is reflected in its share price growth of 27% during 2024, substantially outpacing both the AIM All-Share Index, which declined 5.5%, and the FTSE 250, which gained 5.69%.

This growth was driven by achieving key milestones for portfolio companies, including the successful public listing of two portfolio companies, MicroSalt plc and GenIP, on the AIM market.

MicroSalt had a rip-roaring start to life as a listed company, with shares tripling before falling back. The low-sodium salt technology company announced a ten-fold increase in projected volumes at the beginning of 2025, setting MicroSalt up for another promising year of growth.

The company supplies one of the world’s largest snack food companies with its low-sodium products. It has signalled that the relationship is expanding by announcing increased volumes towards the end of last year, which were followed by encouraging projections. The snack food company remains unnamed, presumably due to the commercial sensitivities of adopting MicroSalt’s technology.

GenIP was listed during a challenging period for the wider market in late 2024 and has set about ramping up its AI-enhanced analytics services aimed at the technology transfer industry. GenIP announced a record order and fresh commercial relationships since listing.

With the listing of GenIP and MicroSalt, four out of Tekcapital’s five portfolio companies are now publicly traded, with the fifth company, Guident, the autonomous vehicle safety company, preparing for a NASDAQ listing in 2025.

Guident may prove to be the jewel in Tekcapital’s crown. Tekcapital is preparing to list Guident at a crucial juncture for autonomous vehicles created by the wider adoption of the technology. Peers listing in the US are attracting bumper valuations, and everything points to a very favourable IPO for Guident.

“We are excited to provide this 2024 summary report which describes a few of our portfolio company achievements and their contribution to our profitability and growth. In 2024 our unaudited net assets reached US$65.1m, an increase of ~36%, over the previous year, with an NAV per share of US $0.31 or £0.25,” said Dr. Clifford M. Gross, Chairman.

“Our performance reflects strong commercial progress through the completion of two AIM listings (MicroSalt plc & GenIP plc) which we are keen to hold. As a result of this progress, four of our five portfolio companies are now listed. Additionally, we observed significant commercial traction for Innovative Eyewear Inc. as they achieved several new product and go-to-market milestones. We were also pleased to note Microsalt has received new and follow-on B2B orders from a major snack food manufacturer. Further, we believe that Guident Corp’s commercial advancements coupled with improving market conditions in the autonomous vehicle industry, have created the ideal opportunity for Tekcapital to further crystalise its balance sheet in 2025.

The Tekcapital Chairman continued to explain the group’s strategy and objective to return capital to investors through special dividends:

“Tekcapital’s core business objective is to grow its net assets and return material levels of capital generated from its portfolio companies’ successes to shareholders via special dividends. As ever, we remain committed to this objective, and our portfolio companies’ progress in 2024 means we have taken strides forward in delivering on our long-term strategy,” Gross explained.

Despite Tekcapital’s strong performance, the stock currently trades at a 64% discount to its Net Asset Value (NAV), a larger gap than its industry peers. For comparison, Molten Ventures plc trades at a 52% discount, IP Group plc at 45%, Frontier IP Group plc at 35%, and Mercia Asset Management plc at 25%. The industry average discount for UK closed-end funds in 2024 was 16.6%, according to Morningstar.

This discount may prove to be an opportunity for investors as general market sentiment improves and Tekcapital completes the Guident IPO, which could significantly increase Tek’s net asset value.

In addition, the company maintains a notably efficient operation, with administrative expenses of just US $2.2 million in 2024, the lowest among its peer group. This lean structure, combined with its strategic focus on a select number of portfolio companies, has contributed to its strong financial performance.

Share Tip: Springfield Properties – this morning’s Interims show that this group is moving at quite a pace

Good news always comes out faster than bad news! 
Like the rest of the market, I was looking for the Scottish-based housebuilding and construction group Springfield Properties (LON:SPR) to announce its Interim Results for the six months to end-November 2024 tomorrow morning, as planned. 
However, the group declared them this morning – they were good and better than expected. 
The group also announced that its is selling 2,480 of its building plots to Barratt Redrow for £64.2m. 
Together those two pieces of news should be positive enough to push the shares forward again.&nbs...

Anglo American outlines platinum unit demerger timeline

Mining giant Anglo American has outlined its June timeline for the separation of Anglo American Platinum, following the platinum company’s release of its 2024 annual results.

Anglo American has scrambled to fight off takeover interest from BHP, and this demerger is one measure undertaken in an attempt to keep the Anglo listing going.

The unit will be listed on both the Johannesburg Stock Exchange and the London Stock Exchange, meaning the London-listed AAL entity will retain some exposure to its platinum business.

Anglo American Platinum has declared dividends amounting to R16.5 billion (approximately £0.7 billion), which comprises both a final dividend for 2024 and an additional cash dividend.

These payments will be distributed to all shareholders before the demerger takes place. As Anglo American currently holds approximately 67 per cent of Anglo American Platinum’s shares, it anticipates receiving roughly £0.5 billion from these dividend payments.

Anglo American Platinum reported adjusted EBITDA for 2024 of R19.8 billion, approximately $1.1 billion.

“We are on a clear timeline towards demerging Anglo American Platinum – the world’s leading PGMs producer – in June, with its primary listing on the Johannesburg Stock Exchange and an additional listing on the London Stock Exchange,” said Duncan Wanblad, Chief Executive of Anglo American.

“Consistent with our commitment to deliver a responsible demerger, Anglo American intends to retain a 19.9% shareholding in Anglo American Platinum in order to further help manage flowback by reducing the absolute size of the shareholding that will be demerged. Anglo American will no longer have any representation on the Anglo American Platinum board post demerger and we intend to exit our residual shareholding responsibly over time, and subject to customary lock-up arrangements.”

ASX-listed Wellnex Life set to join AIM

ASX-listed consumer healthcare company Wellnex Life Ltd (ASX: WNX) is planning to gain an additional quotation on AIM. It currently has a market capitalisation of A$20m.
The company was originally a dairy products business but subsequently moved into consumer healthcare. This has been the focus since 2021.
Wellnex Life has an agreement with Haleon to supply paracetamol products under the Panadol brand. This deal has been expanded outside of Australia and includes the UK and the UAE. There are partnerships with other major pharmaceutical companies. Wellnex Life also has its own brand Pain Away,...

Likewise continues to outperform floorcoverings market

Floorcoverings distributor Likewise Group (LON: LIKE) continues to grow market share on the back of rising revenues despite the decline in its underlying markets. Consumer markets remain tough, but Likewise is showing no signs of decline.
Revenues were 8% ahead in January, following a 10% year-on-year improvement in the fourth quarter. Full year revenues of £150.8m for 2024 were 3% ahead of forecast and 8% higher than the previous year. The market may have fallen by as much as 10% last year.  The overall market is worth less than in 2019.
Solihull-based Likewise has been built up via acqu...

AIM weekly movers: Xeros Technology shares continue to rebound

2

Sustainable laundry technology developer Xeros Technology (LON: XSG) is among the top AIM performers for a second week. Non-exec Klaas de Boer bought 3 million shares at 0.82p each and fellow non-exec David Armfield bought 2.6 million shares at 0.7602p each. Dowgate has increased its shareholding from 11.4% to 13.2%. The estate of William Black has cut its stake from 8.93% to 5.24%. Two weeks ago, Xeros Technology said that it is progressing with tech verification from four global washing machine manufacturers and two of those could move to substantial paid-for joint development agreements. Timing is uncertain, though. The share price recovered a further 73.3% to 1.3p – compared with 0.525p a fortnight ago.

Iron replacement treatment developer Shield Therapeutics (LON: STX) continued its share price recovery last week with a 35% gain to 4.05p, having been 2.8p two weeks ago. This follows the announcement that 2024 revenues were $32.2m as ACCRUFeR sales in the US build up. Management is optimistic that there is enough cash to get to cash flow positive by the end of 2025. Chief executive Anders Lundstrom bought 575,000 shares at 3.7p each, taking his stake to 585,000 shares.

Light Science Technologies (LON: LST) has signed an agreement with Gavita subsidiary Agrolux Nederland to distribute its horticulture lighting products. The deal initially covers the UK and Ireland. Agrolux will sell Light Science Technologies products through its distributor network. Daniel Holliday increased his stake from 10% to 11%. There will be a capital markets day on 26 February.  The share price improved 29.4% to 3.3p.

Serinus Energy (LON: SENX) has won a legal case against the Romanian tax authorities over VAT refunds. The company has been awarded a VAT refund of $1.73m for 2018 and 2019, as well as interest of $750,000. This has to be paid within 45 days. The Romanian operation is loss-making, but there are gas projects that could be developed. The 2024 results are due to be published in March and there should be news concerning how the money will be invested in the business. The share price is 18.7% higher at 2.85p, having been 3.25p earlier on Friday.

FALLERS

Immunodiagnostics developer Oncimmune (LON: ONC) increased revenues by 140% to £2.7m in the 12 months to August 2024. The loss was reduced from £3.9m to £3.2m. Cash was more than £1m at the end of January 2025 with £1.5m of debt outstanding. Strategic partnerships are being explored and additional finance will be sought. The share price slumped 56% to 4p.

Canaccord Genuity reduced its stake in online building products retailer CMO Group (LON: CMO) from 5.37% to 4.31%. The share price slid 55.8% to a new low of 4.25p.

Lord Ashcroft is trying to remove another of his companies from AIM. A general meeting has been requisitioned at wine maker Gusbourne (LON: GUS), where he owns 66.8%. Talks with potential acquirers have ended and the strategic review has been terminated. This follows Lord Ashcroft’s success in getting Merit Group and Jaywing to leave AIM. The share price dived 51.3% to 18.5p.

Drug mathematical modelling company Physiomics (LON: PYC) has raised £430,000 at 0.5p/share and could raise up to £70,000 more from a WRAP retail offer. The offer closes on 17 February. This will finance the expansion of a consulting service and market the biostatistics. It will also fund exploration of a deeper relationship with DoseMe to develop models for its platform. The share price slipped 38.2% to 0.525p.

Aquis weekly movers: All Things Considered for Main Market switch

Ormonde Mining (ORM) has secured three-year renewals for two gold exploration licences in Zamora Province in western Spain. Ormonde Mining plans to acquire the other 51.3% interest in the licences from AIM-quoted cyber security company Shearwater Group (SWG) for five million shares. That is a discount to the implied book value. The Ormonde Mining share price dipped 17.2% to 0.17p.

Music management and event promotion company All Things Considered (ATC) more than doubled 2024 revenues to £50m and EBITDA was £1.5m. Growth is coming from adding managers and new clients, plus acquisitions. Further acquisitions are planned. An agreement has been reached to take the stake in livestreaming platform Driift from 32.5% to 100%. All Things Considered is assessing a move to an unspecified London Stock Exchange market. The share price rebounded 7.69% to 105p.

EDX Medical (EDX) has appointed Martin Walton as deputy chair. He has worked for other life sciences companies, including former AIM company ReNeuron.  The share price rose 5.56% to 9.5p.

In the year to January 2025, EPE Special Opportunities (EO.P) NAV edged up to 328p/share. That includes cash of £11m. Trading was tough for all of the businesses in the portfolio. Investee company Whittard of Chelsea increased like-for-like sales by 6%. Pharmacy2U also grew organically and acquired a business in the pet care market. The share price improved 3.33% to 155p.

FALLERS

Inteliqo Ltd (LON: IQO) wants to cancel the admission to the Aquis Stock Exchange. Inteliqo has been developing and marketing the Langaroo app for a client. It wants to save the costs of the quotation. Trading could end on 14 March if shareholders agree at the general meeting on 27 February. The share price halved to 3p.

Cardiogeni (LON: CGNI) has signed a memorandum of understanding with the private office of Sheikh Al Qassimi for funding of clinical trials. A joint venture will be formed, and it will receive £20m over a period up to 2027 to complete research and clinical trials in the UAE. There will be an initial cash injection of £5m. The cash will fund phase 2b/3 clinical trials and commercialisation of Cardiogeni’s heart failure treatments. The deal could be signed by the end of March 2025. The share price slumped a further 44.4% to 25p.

Valereum (LON: VLRM) is not proceeding with the £2m option agreement with Blue Sky Ventures. Blue Sky was going to subscribe for shares at 10p each. It was previously announced that the option had been exercised. The proposed subscription may be taken on by another investor. The share price dropped 18.6% to 24p. Marula Mining (LON: MARU) has signed the first copper sales agreement for the Kinusi copper mine with a European commodity trader. The initial delivery is 250 tonnes of copper concentrate based on 20% copper grade. The income is linked to the LME copper price with additional payments for gold and silver content. The first revenues should be received in this quarter. After successfully delivery, there will be more each month that will total up to 1,000 tonnes. There are three other potential offtake agreements. Kinui has reached a milestone, so $200,000 of shares have been issued to Takela Mining Tanzania at 6p each. Marula Mining has also paid the final consideration of £625,000 for Northern Cape Lithium and Tungsten in the form of 20.83 million shares at 6p each. Modifications to the plant at the Kilifi processing plant in Kenya should be completed in the second quarter. As part of the drawdown agreement, AUO Commercial Brokerage has subscribed for £500,000 worth of shares at 3.75p/share. The share price slipped 18.4% to 5p/share.